Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

32.1%

26 terminated/withdrawn out of 81 trials

Success Rate

53.6%

-32.9% vs industry average

Late-Stage Pipeline

11%

9 trials in Phase 3/4

Results Transparency

67%

20 of 30 completed trials have results

Key Signals

8 recruiting20 with results25 terminated

Enrollment Performance

Analytics

Phase 1

41(53.2%)

Phase 2

27(35.1%)

Phase 3

9(11.7%)

77Total

Phase 1(41)

Phase 2(27)

Phase 3(9)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (81)

Showing 20 of 81 trials

NCT07601399Unknown

An EAP Treatment Protocol of Zipalertinib

Role: lead

NCT02693535Phase 2Recruiting

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Role: collaborator

NCT06506955Phase 2Enrolling By Invitation

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

Role: lead

NCT05967689Phase 2Recruiting

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

Role: lead

NCT04953897Phase 1Recruiting

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

Role: lead

NCT05973773Phase 3Active Not Recruiting

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

Role: lead

NCT07128199Phase 3Active Not Recruiting

A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

Role: lead

NCT04953910Phase 1Recruiting

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

Role: lead

NCT05727176Phase 2Recruiting

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

Role: lead

NCT05615818Phase 3Recruiting

Personalized Medicine for Advanced Biliary Cancer Patients

Role: collaborator

NCT04256317Phase 2Recruiting

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Role: lead

NCT05396859Phase 1Active Not Recruiting

Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia

Role: collaborator

NCT05945823Phase 2Active Not Recruiting

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Role: lead

NCT05765734Phase 1Terminated

A Study of TAS3351 in NSCLC Patients With EGFRmt

Role: lead

NCT04980404Phase 1Active Not Recruiting

Inqovi Maintenance Therapy in Myeloid Neoplasms

Role: collaborator

NCT04742634Phase 1Recruiting

Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant

Role: collaborator

NCT02503423Phase 1Active Not Recruiting

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

Role: lead

NCT03223779Phase 1Completed

Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer

Role: collaborator

NCT03502668Phase 1Completed

Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS

Role: lead

NCT04507503Unknown

Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Role: lead